In Clinical Trials: A Potential Self-Administered Treatment for Diabetic Macular Edema

Aerpio Therapeutics, Inc. is a new Cincinnati, Ohio-based biopharmaceutical company focused on developing new therapies for vascular [i.e., blood vessel] diseases, including diabetic macular edema (DME) and age-related macular degeneration (AMD). This week, Aerpio announced positive clinical trial results for AKB-9778, which shows potential for self-administered subcutaneous [i.e., beneath-the-skin injection] treatment of DME, offering an … Continued

The FDA Approves EYLEA Injection for the Treatment of Diabetic Macular Edema

Some good news for individuals who have diabetes and associated diabetic macular edema: On July 29, 2014, the United States Food and Drug Administration (FDA) approved EYLEA (generic name aflibercept) for the treatment of diabetic macular edema. The recommended dosage is two milligrams (mg) every two months, after five initial monthly injections. About Diabetic Macular … Continued

Do Doctors Approach Macular Degeneration Differently When Treating Themselves?

Do retinal physicians approach wet age-related macular degeneration differently when treating themselves versus treating their patients? This question was explored in a recent presentation by Jonathan Prenner, M.D., at the 32nd Annual Meeting of the American Society of Retina Specialists in San Diego, California. The mission of the American Society of Retina Specialists is to … Continued

Is a “Treat and Extend” Injection Regimen More Beneficial for Wet Macular Degeneration?

The treatment of wet age-related macular degeneration (AMD) has – by all accounts – been revolutionized by the successful use of the injectable drugs Eylea, Lucentis, and Avastin. Yet, despite this treatment revolution, significant questions remain about the most effective dosing schedule for these medications: Is it monthly injections, a pro re nata [i.e., “as … Continued

New Research: Are Lucentis, Avastin, and Eylea Risk Factors for Increased Eye Pressure?

The injectable drugs Eylea, Lucentis, and Avastin have revolutionized the treatment of wet age-related macular degeneration (AMD). Nevertheless, questions continue to arise regarding the risks and complications that accompany this delivery system. At present, these drugs require monthly injections or a pro re nata [i.e., “as needed”] (PRN) regimen, with monthly controls and injections for … Continued

Meet the Discovery Eye Foundation and the Macular Degeneration Partnership

The Discovery Eye Foundation, headquartered in Los Angeles, California, has become an important ally of, especially in the area of patient education for macular degeneration. The primary mission of the Discovery Eye Foundation is twofold: Funding cutting-edge research to find new treatments and cures for retinal and corneal eye diseases Empowering people with up-to-date, … Continued

A Potential Intravenous Treatment for Wet Age-Related Macular Degeneration: Interleukin-18

A research group, composed of members from the Republic of Ireland, the United Kingdom, and the United States, has determined that a protein called interleukin-18 (IL-18), which is a component of the immune system linked to inflammatory disorders, has the ability to suppress production of the harmful bleeding/leaking blood vessels that characterize wet age-related macular … Continued

A Potential Eye Drop Treatment for Wet and Dry Macular Degeneration

Researchers have identified a possible topical [i.e., eye drop] treatment for age-related macular degeneration (AMD) that is capable of inhibiting the characteristic symptoms of both the dry and wet forms of AMD. This “proof of concept” research is in its earliest stages and has been conducted only with laboratory mice. Nevertheless, the concept of a … Continued

Newest Therapies for Macular Degeneration are Reducing Vision Loss and Admissions to Long-Term Care

Here is some good news during National Age-Related Macular Degeneration Awareness Month. Two economists from Duke University have presented evidence that within the past ten years, since the introduction of anti-VEGF therapies (Lucentis, Avastin, and Eylea), older Americans with “wet” or exudative macular degeneration are less likely to experience vision loss and less likely to … Continued

Eylea May Help When Patients Do not Respond to Lucentis or Avastin for Macular Degeneration

A new study, published “online first” on May 23, 2013 in the American Journal of Ophthalmology, concludes that Eylea therapy appears to be beneficial in a specific group of patients with wet age-related macular degeneration (AMD) whose symptoms are not responsive to either Lucentis or Avastin injections. The American Journal of Ophthalmology is a peer-reviewed, … Continued